Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors. Its pipeline includes CARs (Chimeric antigen receptors), TILs (Tumor-infiltrating lymphocytes), and TCRs (T cell receptors). Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors. Its pipeline includes CARs (Chimeric antigen receptors), TILs (Tumor-infiltrating lymphocytes), and TCRs (T cell receptors).
Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3rd line+ setting in 2025 and expect to initiate a pivotal trial in the 2nd line by early...
Objective response rate (ORR) of 94% and a complete response (CR) rate of 71% demonstrated after IMPT-314 treatment in CAR T-naïve patients with large B-cell lymphoma who had received at least 2...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0286 | -4.68929332677 | 0.6099 | 0.6355 | 0.5545 | 816155 | 0.59710498 | CS |
| 4 | -0.0417 | -6.69341894061 | 0.623 | 0.6522 | 0.5505 | 852277 | 0.59121788 | CS |
| 12 | -0.5287 | -47.6306306306 | 1.11 | 1.16 | 0.5505 | 1171128 | 0.76740598 | CS |
| 26 | -0.8387 | -59.0633802817 | 1.42 | 1.62 | 0.5505 | 1102979 | 0.99376086 | CS |
| 52 | -1.2087 | -67.5251396648 | 1.79 | 3.2556 | 0.5505 | 1011323 | 1.50008903 | CS |
| 156 | -5.0887 | -89.7477954145 | 5.67 | 8.74 | 0.5505 | 1053760 | 3.17383066 | CS |
| 260 | -18.1687 | -96.8997333333 | 18.75 | 19.84 | 0.5505 | 961397 | 3.99697212 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
